KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBT (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBT for 16 consecutive years, with $50000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 108.82% year-over-year to $50000.0, compared with a TTM value of $10000.0 through Sep 2025, up 100.25%, and an annual FY2024 reading of -$2.3 million, up 69.74% over the prior year.
  • EBT was $50000.0 for Q3 2025 at TherapeuticsMD, down from $545000.0 in the prior quarter.
  • Across five years, EBT topped out at $48.5 million in Q4 2022 and bottomed at -$47.4 million in Q3 2021.
  • Average EBT over 5 years is -$9.6 million, with a median of -$1.6 million recorded in 2023.
  • The sharpest move saw EBT surged 212.79% in 2022, then plummeted 103.27% in 2023.
  • Year by year, EBT stood at -$43.0 million in 2021, then soared by 212.79% to $48.5 million in 2022, then tumbled by 103.27% to -$1.6 million in 2023, then skyrocketed by 105.24% to $83000.0 in 2024, then crashed by 39.76% to $50000.0 in 2025.
  • Business Quant data shows EBT for TXMD at $50000.0 in Q3 2025, $545000.0 in Q2 2025, and -$668000.0 in Q1 2025.